Online Message
After receiving your message, our professional team will contact you shortly.
Antibody/Biologics R&D Services
Bispecific Antibody Platform
Viva Biologics boasts extensive experience in the development of bispecific antibodies, with mature technologies encompassing the design, expression, and purification processes. By integrating CADD/AIDD technologies, we are also capable of assisting clients in drugability evaluation, affinity maturation, and patent circumvention for bispecific antibodies. In summary, we are equipped to deliver high-quality, one-stop bispecific antibody development services.Furthermore, Viva Biotech has entered into a license agreement with Lonza to obtain access to Lonza's bYlok® bispecific pairing technology. This access significantly enhances Viva Biotech's capabilities in large molecules by facilitating the design and production of bispecific antibodies. Lonza's bYlok® technology platform effectively addresses the challenge of heavy-light chain mispairing and enhances the production efficiency and quality of bispecific antibodies.
-
Case StudyCase Study - Bispecific Ab
Case Study - Bispecific Ab
Case Study - Bispecific Ab
Case Study - Bispecific Ab Engineering
-
Lonza's bYlok® Bispecific Antibody Platform
The platform offers several advantages, including high expression levels, stability and affinity comparable to monoclonal antibodies, and high recovery rate. Additionally, it comes with a highly cost-effective licensing price.
Fab-ARm EXchange (FAE) BsAB Design
QC Analysis fOr FAE Case
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号
- About Us
-
CRO Services
BackCRO ServicesDiscovery Biology Services
- CDMO Services
- EFS Business
- News
- Careers
- Investor Relations
- Contact Us